
    
      This is a randomized, double-blind, placebo-controlled study that will assess the safety,
      efficacy, and PK of miricorilant in obese patients with schizophrenia or bipolar disorder who
      are currently taking oral or injectable atypical antipsychotic medication.

      Patients who meet the criteria for the Study CORT118335-876 will be randomized on Day 1 to
      receive 600 mg miricorilant or placebo for 12 weeks.
    
  